Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday

Castle Biosciences (NASDAQ:CSTL) will likely be posting its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect Castle Biosciences to post earnings of ($0.35) per share and revenue of $71.0620 million for the quarter. Castle Biosciences has set its FY 2025 guidance at EPS.Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.66. The firm had revenue of $86.18 million during the quarter, compared to analysts’ expectations of $71.53 million. Castle Biosciences had a positive return on equity of 2.37% and a negative net margin of 2.73%. On average, analysts expect Castle Biosciences to post $0 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Castle Biosciences Stock Performance

NASDAQ:CSTL opened at $25.50 on Friday. The company has a market cap of $739.76 million, a price-to-earnings ratio of -72.86 and a beta of 1.13. Castle Biosciences has a fifty-two week low of $14.59 and a fifty-two week high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.69 and a current ratio of 6.85. The stock has a fifty day moving average price of $23.14 and a 200-day moving average price of $20.08.

Insider Activity

In related news, insider Derek J. Maetzold sold 1,339 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $22.44, for a total transaction of $30,047.16. Following the sale, the insider owned 62,988 shares in the company, valued at $1,413,450.72. The trade was a 2.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Castle Biosciences

Several large investors have recently modified their holdings of CSTL. Jones Financial Companies Lllp grew its stake in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Castle Biosciences by 256.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,791 shares of the company’s stock worth $57,000 after buying an additional 2,009 shares in the last quarter. Amundi grew its position in shares of Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after buying an additional 4,111 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Castle Biosciences during the 2nd quarter worth approximately $211,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Castle Biosciences by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after acquiring an additional 655 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 10th. Canaccord Genuity Group reiterated a “buy” rating and set a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, September 9th. Finally, Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $36.57.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.